Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1301-1320 of 1,738 trials

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

RR001 Gene Therapy for Locally Advanced Pancreatic Cancer

We are studying a new gene therapy combined with chemotherapy to see if it is safe and effective for patients with locally advanced pancreatic cancer. The trial will help determine the best dose and how well this treatment works.

Pancreatic CancerLocally Advanced Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Graves' Disease: IMVT-1402 Treatment Study

We are studying a new treatment called IMVT-1402 for adults with Graves' disease. The aim is to see if it can improve thyroid hormone levels compared to a placebo.

Grave's Disease1-2 yearsEfficacy phase (II)Investigational MedicinesEndocrinology

Chronic Kidney Disease: Dapagliflozin and Balcinrenone Study

We are investigating how dapagliflozin, alone or with balcinrenone, affects kidney function and fluid balance in people over 50 with chronic kidney disease. This study aims to understand the potential benefits of these treatments on energy metabolism and urine concentration.

Stage 3 Chronic Kidney Disease1-2 yearsEfficacy phase (II)Investigational MedicinesEndocrinologyNephrology

Ifinatamab Deruxtecan for Metastatic Prostate Cancer

We are studying ifinatamab deruxtecan to see if it is safe and effective for men with metastatic castration-resistant prostate cancer. This trial will help us understand how well it works compared to other treatments.

Metastatic Castrate Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Migraine Aura: Amiloride Study

We are investigating whether amiloride can help prevent migraine aura and headaches in people who experience these symptoms. The study will also assess the safety of this medication.

Migraine Aura6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInternal MedicineNeurology

Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib for patients with Chronic Myeloid Leukemia who have the T315I mutation and have not responded to ponatinib. The trial aims to see how well it works and how safe it is.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOphthalmology

Ewing Sarcoma: Comparing Chemotherapy Treatments

We are studying different chemotherapy regimens for patients with recurrent or refractory Ewing Sarcoma. Our goal is to find the most effective and patient-friendly treatment option.

Ewing's Sarcoma3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer Imaging: 99mTc-MIP-1404 SPECT/CT Study

We are comparing a new imaging technique to standard methods for detecting prostate cancer spread in patients. This study aims to see if the new method improves detection of lymph node and bone metastases.

Prostate Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesOtolaryngologyUrology

Pulmonary Tuberculosis: Cysteamine Therapy Study

We are investigating the safety of cysteamine as an additional treatment for adults with pulmonary tuberculosis. This study aims to see how it affects bacterial load and immune response during standard TB therapy.

Pulmonary Tuberculosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

CAR T Cell Therapy for Acute Leukemia in Young Patients

We are studying a new treatment using donor-derived CAR T cells for children and young adults with recurrent acute leukemia. The trial aims to assess the safety and effectiveness of this therapy after previous stem cell transplantation.

Recurrent Acute Lymphocytic Leukaemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Preventing Relapses in Minimal Change Nephrotic Syndrome with Rituximab

We are studying whether Rituximab can help adults with Minimal Change Nephrotic Syndrome stay in remission after their first episode. This trial looks at the effectiveness and safety of the treatment over time.

Minimal Change Nephrotic Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNephrology

GRAALL2014: Clinical Trial Study

We are investigating a new treatment approach for a specific health condition. This trial aims to understand its effects and potential benefits for participants.

Acute Lymphoblastic Leukemia (ALL)>2 yearsEfficacy phase (II)Internal Medicine

Ruxolitinib for Children with Hemophagocytic Lymphohistiocytosis

We are studying whether Ruxolitinib, combined with corticosteroids, can improve survival in children with HLH until they receive a stem cell transplant. The trial will also look at how well the treatment works and any side effects.

Haemophagocytic Lymphohistiocytosis in Children>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Acute Myeloid Leukemia: Venetoclax vs. Intensive Chemotherapy

We are studying whether venetoclax with low-dose cytarabine can improve outcomes for patients with favorable risk acute myeloid leukemia compared to intensive chemotherapy. This trial will help us understand the best treatment options for this condition.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cancer Imaging: New Non-Invasive Technique

We are exploring a new imaging method that combines two techniques to study how cancer cells and healthy tissues use energy. This may help improve cancer diagnosis and treatment strategies.

Pancreatic Neuroendocrine TumorNeuroendocrine CarcinomaSoft Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementAllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Breast Cancer Treatment: Fulvestrant with Palbociclib

We are studying whether combining fulvestrant with palbociclib helps postmenopausal women with hormone receptor-positive metastatic breast cancer live longer without disease progression compared to fulvestrant alone. This trial is for women who have completed at least five years of hormonal therapy and remained disease-free for over a year, or who have newly diagnosed metastatic disease.

Metastatic Breast Cancer1-2 yearsEfficacy phase (II)Standard MedicinesOncology

HIV-1 Infection: ART with Long-Acting Antibodies

We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.

HIV-1 Infection>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Immunotherapy for Cutaneous Squamous Cell Carcinoma

We are studying whether immunotherapy can help patients with skin cancer achieve remission without surgery or radiation. This trial aims to assess the treatment's effectiveness and safety over time.

Skin Cancer (Cutaneous Squamous Cell Carcinoma)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology